Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant

Although Quark initially expects to market the drug as a treatment for a rare condition known as non-arteritic anterior ischemic optic neuropathy, it hopes it can eventually develop it as a glaucoma treatment.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.